Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.80.

Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Regulus Therapeutics Trading Down 6.3 %

Shares of Regulus Therapeutics stock traded down $0.08 during trading hours on Thursday, reaching $1.19. The stock had a trading volume of 539,735 shares, compared to its average volume of 833,579. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.79. The firm has a market capitalization of $77.95 million, a price-to-earnings ratio of -1.11 and a beta of 1.58. The firm has a 50 day simple moving average of $1.42 and a two-hundred day simple moving average of $1.52.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Sell-side analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current year.

Insider Buying and Selling at Regulus Therapeutics

In other news, insider Preston Klassen sold 31,445 shares of Regulus Therapeutics stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $39,620.70. Following the sale, the insider now directly owns 36,055 shares of the company's stock, valued at approximately $45,429.30. The trade was a 46.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph P. Hagan sold 115,290 shares of the business's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the transaction, the chief executive officer now owns 222,572 shares in the company, valued at approximately $280,440.72. This trade represents a 34.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 223,998 shares of company stock valued at $282,237 over the last 90 days. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of Regulus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RGLS. NEA Management Company LLC acquired a new position in shares of Regulus Therapeutics in the 3rd quarter valued at about $10,154,000. Point72 Asset Management L.P. bought a new position in Regulus Therapeutics in the third quarter worth about $1,403,000. The Manufacturers Life Insurance Company acquired a new position in Regulus Therapeutics in the third quarter valued at approximately $204,000. Tyche Wealth Partners LLC boosted its stake in Regulus Therapeutics by 920.6% in the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company's stock valued at $167,000 after acquiring an additional 95,694 shares during the period. Finally, Barclays PLC grew its holdings in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 62,549 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.